APN News

  • Thursday, April, 2019| Today's Market | Current Time: 09:42:55
  • Scottsdale, Arizona : Military personnel, athletes and accident victims who experience concussions can suffer from painful and debilitating conditions that impact everyday activities. Persisting symptoms from these mild Traumatic Brain Injuries (mTBI) can include sleep disturbance, anxiety, depression, foggy thinking, headaches, dizziness and behavioral issues.

    That’s why Cereset is proud to announce its patented BrainEcho™ technology will be used in a randomized research trial for individuals with persisting symptoms following mTBI.

    The objective of the study is to measure the efficacy of a non-invasive de novo technology which compares tones delivered to a subject’s brain guided by the brain’s own rhythms, versus random unguided tones. The research trial will be conducted in two locations to work with active and retired military, as well as military family members, who experienced a TBI in the last 10 years.

    A full description of the study can be found at Clinical Trials.gov at: https://clinicaltrials.gov/ct2/show/NCT03649958

    “Our entire team is thrilled to participate in this clinical trial to demonstrate how our new Cereset Research technology may help U.S. military personnel and their family members suffering with mTBI,” said Lee Gerdes, Founder and CEO of Cereset and parent company Brain State Technologies. “I created this technology initially to help myself following my own head injury from an assault with a baseball bat. This technology was the only thing I found that reduced my symptoms and helped me have restorative sleep.”

    mTBI has been called the “signature injury” of the wars in Iraq and Afghanistan, with up to 80% of battle injuries attributable to concussive shock waves from an improvised explosive device (IED). It can cause debilitating conditions such as trouble sleeping and anxiety, and it’s generally accepted that Post-Traumatic Stress Disorder (PTSD) often co-occurs with persisting mTBI.

    In addition, an estimated 190,000 individuals yearly develop persisting symptoms following a concussion (mTBI) suffered while playing sports or during recreational activity. Professional guidelines now state that returning to competition should not rely on medications that may mask symptoms which would prevent an athlete’s return to play. Not only can persisting symptoms put individuals at risk for an end to their athletic careers, they may interfere with, or even prevent, participation in non-athletic and academic activities.

    Legacy Cereset Research technology has been used in past clinical trials at Wake Forest School of Medicine under the direction of Doctor Charles Tegeler, Professor of Neurology. Doctor Tegeler’s findings with PTSD and athletes with persisting-post concussion symptoms were instrumental in securing a $2.8M grant from the Office of the Assistant Secretary of Defense for Health/Traumatic Brain Injury Research Program, under Award No. W81XWH-17-2-0057. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. The U.S. Army Medical Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.

    Wake Forest School of Medicine is collaborating in this research through Doctor Tegeler’s involvement as a Co-Investigator. Lee Gerdes, Cereset/Brain State is the project’s Principal Investigator; Co-Investigators include Doctor Michael Roy and Doctor Wesley Cole.

    Loading...